Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 2Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Neoadjuvant Therapy 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced NSCLC 1

Interventions

Carboplatin 191Cisplatin 157Pemetrexed 152Paclitaxel 127Docetaxel 109pembrolizumab 87Gemcitabine 73Erlotinib Hydrochloride 44Radiotherapy 39Vinorelbine 35Gefitinib 34durvalumab 31Bevacizumab 28Nivolumab 26Drug Therapy 23atezolizumab 22osimertinib 19130-nm albumin-bound paclitaxel 19tislelizumab 17Crizotinib 16Radiosurgery 15Etoposide 14Surgical Procedures, Operative 11Afatinib 11Ipilimumab 10icotinib 9aumolertinib 9Albumin-Bound Paclitaxel 9Specimen Handling 8Observation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Non-Small-Cell Lung × famitinib × Clear all
NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
450 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡